Enzo Biochem Stock

Enzo Biochem FCF Conversion

Delisted·Apr 17, 2025

The FCF Conversion Rate (FCF/EBITDA) of Enzo Biochem (ENZ) as of Aug 5, 2026 is 335.05 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 152.37 % — a change of 119.89% (higher).

FCF Conversion

335.05 %

YoY

119.89%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Enzo Biochem is 2026 335.05 % . FCF Conversion Rate (FCF/EBITDA) of Enzo Biochem was 2025 152.37 % . It decreases by 119.89% higher compared to the previous year.
Access this data via the Eulerpool API

Enzo Biochem Stock analysis

What does Enzo Biochem do? Enzo Biochem Inc is a US-based company operating in the biotechnology sector. It was founded in 1976 by Elazar Rabbani and is headquartered in New York. The company focuses on developing, producing, and marketing innovative diagnostic and therapeutic products for the medical industry. Enzo Biochem Inc's business model is based on the application of modern technologies for the development and synthesis of molecules for medical technology and life sciences. At the same time, the company also offers diagnostic testing systems and clinical laboratory services to its customers. Enzo Biochem's business model is therefore diverse and covers various areas. Enzo Biochem divides its business into three main segments: life sciences, clinical labs, and therapeutics. In the life sciences segment, the company engages in research and development of technologies for synthesizing molecules for medical technology. In the clinical labs segment, Enzo Biochem offers diagnostic testing systems and clinical laboratory services for use in medical diagnostics. The therapeutics segment manufactures therapeutic products for the treatment of viral infections. Enzo Biochem's product offering includes a wide range of products and services. This includes molecules for medical technology, diagnostic testing systems, and therapy products for viral infections. The product lines of Enzo Biochem include: - Molecules for medical technology: Enzo Biochem has developed a wide range of molecules for medical technology and is a leader in this field. These molecules include proteins, antibodies, and other biomolecules. The company also offers custom molecules for specific applications. - Diagnostic testing systems: The company offers a wide range of diagnostic testing systems tailored to the needs of laboratories and clinics. The tests include tests for infectious diseases, cancer, metabolic disorders, and other diseases. - Clinical laboratory services: Enzo Biochem provides a wide range of clinical laboratory services, including blood tests, microbiological tests, urine, stool, and body fluid tests, as well as histological analysis of tissue samples. - Therapy products: Enzo Biochem has developed a broad portfolio of therapy products for the treatment of viral infections. These products include immunomodulators, antivirals, and other therapeutics aimed at combating various pathogens. Enzo Biochem has made a name for itself in the biotechnology industry through continuous innovation and high-quality products. The company has also engaged in partnerships, acquisitions, and joint ventures to expand its global footprint. It has a global presence and works with leading pharmaceutical and biotech companies from around the world. Overall, Enzo Biochem has established itself as a leading biotechnology company operating in the fields of life sciences, clinical labs, and therapeutics. The company offers a wide range of products and services tailored to the needs of laboratories and clinics. Enzo Biochem has established itself as an innovation leader in the biotechnology industry and is committed to further expanding its business through the development of new products and technologies. Enzo Biochem is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Enzo Biochem stock

FCF Conversion Rate (FCF/EBITDA) of Enzo Biochem is 335.05 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Enzo Biochem changed from 152.37 % to 335.05 %, representing a 119.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Enzo Biochem since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Enzo Biochem with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Enzo Biochem

All Key Metrics — Enzo Biochem